Medtronic Plc. announced the launch of a new hybrid closed-loop system for North America & Europe artificial pancreas systems market

 

North America & Europe Artificial Pancreas Systems Market

The increasing incidence of type 1 diabetes is significantly fueling the growth of the North America & Europe artificial pancreas systems market. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., around 40,000 people are diagnosed with Type 1 diabetes, annually, and by 2050, 5 million people are expected to be diagnosed with the disease, in the country. Moreover, Germany had the highest prevalence of diabetes in Europe among their adult population with 15.3 percent living with diabetes in 2019, Portugal followed with the second-highest share at 14.2 percent. Furthermore, the growing adoption of high-end systems in diabetes management is further projected to foster the growth of the North America & Europe artificial pancreas systems market.

North America region is expected to hold a dominant position in North America & Europe artificial pancreas systems market and this is attributed to the presence of a well-established healthcare sector and high prevalence of diabetes disease in the region.

1.      In June 2017, Medtronic Plc. announced the launch of a new hybrid closed-loop system (near-artificial pancreas) for people with type 1 diabetes in the U.S

2.      In January 2020, Medtech Company Beta Bionics has received the FDA Breakthrough Device designation for its automated bionic pancreas – the iLet Bionic Pancreas System. The iLet Bionic Pancreas System is a pocket-sized, wearable investigational medical device that is designed to autonomously control blood-sugar levels.

3.      In January 2021, Medtronic launched The MiniMed 780G system, an advanced hybrid closed-loop insulin delivery system aimed at simplifying the management of type 1 diabetes

The introduction of hybrid closed-loop artificial pancreas systems is expected to provide potential growth opportunities for players in North America and Europe artificial pancreas systems market. For instance, in December 2019, Tandem Diabetes Care, Inc. received the U.S. FDA clearance for its t: slim X2 insulin pump with Control-IQ technology, an advanced hybrid-closed loop feature.

There are many different types of artificial pancreas systems available in the market today, but the most popular among them is the mechanical type which basically is mechanical like pumps, which is used for controlling the secretion of human insulin into the bloodstream. The process of having an artificial pancreas involves the introduction of an infusion pump or some type of electronic device that will allow the insulin, into the body. There are many benefits that an artificial pancreas system can offer. The most common positive effect of an artificial pancreas is the prevention of insulin shock.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

Increased Prevalence of Chronic Diseases and Stem Cell Therapy R&D to Drive Stem Cell Assay Market Growth